Metoprolol vs Amlodipine: side effects in FDA adverse event reports
At a glance
| Metoprolol | Amlodipine | |
|---|---|---|
| Drug class | – | – |
| Brand names | Metoprolol Tartrate | Katerzia |
| FAERS reports | 271,764 | 267,918 |
| Serious | 70% | 77% |
| Death outcome | 30,898 | 29,515 |
| Boxed warning | No | No |
Signals both drugs share
| Reaction | Metoprolol | Amlodipine | Label screen (A / B) |
|---|---|---|---|
| Chronic kidney disease | 5,602 · PRR 6.0 | 5,408 · PRR 5.9 | Likely indication confounding / Likely indication confounding |
| End stage renal disease | 2,145 · PRR 10.0 | 1,985 · PRR 9.3 | Not in label — unassessed / Not in label — unassessed |
| Nephrogenic anaemia | 1,014 · PRR 21.2 | 961 · PRR 20.0 | Not in label — unassessed / Not in label — unassessed |
| Suspected suicide | 321 · PRR 5.5 | 787 · PRR 15.3 | Likely indication confounding / Likely indication confounding |
| Hyperparathyroidism secondary | 532 · PRR 20.3 | 546 · PRR 21.3 | Not in label — unassessed / Not in label — unassessed |
| Brash syndrome | 595 · PRR 60.1 | 245 · PRR 17.1 | Not in label — unassessed / Not in label — unassessed |
| Rebound acid hypersecretion | 415 · PRR 11.9 | 347 · PRR 9.9 | Not in label — unassessed / Not in label — unassessed |
| Atrioventricular block first degree | 327 · PRR 6.2 | 299 · PRR 5.7 | Not in label — unassessed / Not in label — unassessed |
| Left ventricular hypertrophy | 279 · PRR 5.3 | 301 · PRR 5.8 | Likely indication confounding / Likely indication confounding |
| Diastolic dysfunction | 215 · PRR 5.7 | 232 · PRR 6.2 | Likely indication confounding / Likely indication confounding |
| Chronic kidney disease-mineral and bone disorder | 223 · PRR 20.0 | 221 · PRR 20.0 | Not in label — unassessed / Not in label — unassessed |
Labeled signals distinctive to Metoprolol
- Bradycardia — n=3,427, PRR 5.3 Labeled adverse reaction
- Coronary artery disease — n=2,442, PRR 6.6 Labeled adverse reaction
- Sinus bradycardia — n=625, PRR 5.3 Labeled (related wording)
- Angina unstable — n=543, PRR 6.9 Labeled (related wording)
- Coronary arterial stent insertion — n=352, PRR 5.7 Labeled (related wording)
- Rhinitis allergic — n=337, PRR 6.3 Labeled (related wording)
- Hypertensive emergency — n=168, PRR 12.8 Labeled (related wording)
Labeled signals distinctive to Amlodipine
- None stood out among the strongest labeled signals.
Common questions
Which has more reported side effects, Metoprolol or Amlodipine?
Metoprolol has 271,764 FAERS reports and Amlodipine 267,918. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (70% vs 77%) is a better like-for-like signal of the kind of problems reported.
Which side effects do Metoprolol and Amlodipine share?
Both drugs carry disproportionality signals for chronic kidney disease, end stage renal disease, nephrogenic anaemia, suspected suicide, hyperparathyroidism secondary. Shared signals often reflect a shared drug class or the condition both are used for.
Is Metoprolol or Amlodipine safer?
FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.
Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.